Delivery Order SPE2DR25D1109-SPE2DR26FFJ5P
- Not listed
- The Defense Logistics Agency awarded a $7,635.64 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on December 2, 2025, with completion scheduled for December 3, 2025. This firm fixed price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $23,153.27 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on December 8, 2025, with completion scheduled for December 9, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor will perform this...
- The Defense Logistics Agency awarded a $24,528.85 delivery order to AmerisourceBergen Drug Corp on December 16, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30, with completion expected by December 17, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and regularly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for supply of RINVOQ ER 15 mg tablets (30-count units) under a firm fixed price contract valued at $11,902.23. This is a non-set-aside competitive award with an ultimate completion date of December 11, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $14,136.53 for RINVOQ ER 15 mg tablets (30-count units) on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a $8,996.88 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on December 11, 2025, with a completion deadline of December 12, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order has a ceiling value of $87,963.69 and an ultimate completion date of December 10, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13.5K to AmerisourceBergen Drug Corp on December 16, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The work is scheduled for completion by December 17, 2025, with performance taking place at the contractor's corporate office in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on December 16, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units) at a ceiling value of $3,279.20. This firm fixed-price, non-set-aside delivery order represents a competitive procurement action with an ultimate completion date of December 17, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) with a ceiling value of $6,827.22. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of November 25, 2025. This delivery order...
- SPE2DR25D1109Indefinite Delivery Contract
- SPE2DR25D1109-SPE2DR26FFJ5PDelivery Order
The Defense Logistics Agency awarded a $20,993.74 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed price structure. The award, issued on December 23, 2025, is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical. The ultimate completion date is set for December 24, 2025, and performance will take place at the contractor's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains a significant prime IDC with DLA valued at $999,999,999.00 through December 2026. This comprehensive vehicle enables the company to supply a broad range of pharmaceutical products, medical supplies, vaccines, and specialized healthcare commodities to support military healthcare programs worldwide, including customers such as the Defense Health Agency and U.S. Coast Guard. The firm's consistent receipt of competitively awarded delivery orders across multiple therapeutic domains demonstrates its established capability to meet federal medical procurement requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.0k | 12/22/25 |